Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs ...

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden ...

As well, Novo Nordisk® has earlier announced a successful outcome of a human trial of 3,533 people with CKD and type 2 diabetes using injected semaglutide. The study 'demonstrated a statistically ...

sold by Eli Lilly and Novo Nordisk. Amgen’s study was among the most closely-watched in the obesity field this year, with ...

The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

Healthcare looks to be entering a golden age, driven by demographic shifts that look capable of driving growth for years, if not decades, to come.

France said Wednesday that it 'intends to continue to work in close collaboration' with Israeli Prime Minister Benjamin Netanyahu despite an arrest warrant issued for him by the world’s top war crimes ...

Amsterdam-based Cradle, an AI-powered platform revolutionising protein engineering, has secured $73 million in Series B funding to meet growing demand in research-intensive industries. Led by IVP with ...

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.